Proteasome Inhibitors
1 drugsAbout Proteasome
The proteasome is a large protein complex responsible for degrading unneeded or damaged proteins through proteolysis. This function is critical for cellular regulation, making it a therapeutic target.
Inhibiting the proteasome disrupts protein degradation, leading to cell death, especially in rapidly dividing cancer cells. Currently, there is no genetic evidence directly linking the proteasome to specific diseases.
The proteasome is targeted by one FDA-approved drug, NINLARO (Takeda), a small molecule used in oncology. NINLARO was first approved in 2015.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Recurrent Waldenstrom Macroglobulinemia with only 1 trials.
- phase1 represents biological uncertainty with 52% completion.
Top Drugs
Takeda is the only company with an approved drug targeting the proteasome.
Low competition indicates a potential market opportunity, but also a higher risk due to lack of validation by multiple players.
Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Proteasome, using small molecule modality.
The lack of modality diversity suggests an opportunity to explore alternative approaches like antibodies or PROTACs.
Clinical Trials 126 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 55 | 30 | 12 | 13 | 71% |
| Phase 2 | 53 | 27 | 13 | 13 | 68% |
| Phase 3 | 10 | 8 | 1 | 1 | 89% |
| Phase 4 | 8 | 4 | 2 | 2 | 67% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Drug Approval Timeline (2015 - 2015)
The first and only drug, NINLARO, was approved in 2015.
The lack of recent approvals suggests potential saturation or challenges in developing new proteasome inhibitors.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 93 clinical trials targeting Proteasome.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities